Print page

Patheon Starts Oral Contraceptive Production in Toronto

PharmaManufacturing.com
05/19/2009

Patheon Inc. announces the expansion of its Toronto manufacturing facility. The expansion adds 10,000 square feet of GMP space dedicated to the production of oral contraceptives with a potential output of 1.3 billion tablets. This includes full-scale commercial production capabilities, including dispensing, granulation, compression, film coating and primary packaging. The new area will utilize abatement technology, which is used for the elimination of solvent emissions and meets projected 2020 Ministry of Environment Standards.

The expansion of dedicated space for the production of oral contraceptives is a regulatory requirement to sell in many countries. By providing dedicated space, Patheon will free up manufacturing capacity in the Toronto facility for current and new commercial business and allow for future growth within the Pharmaceutical Development Services area. The newly expanded Toronto site will be a Center of Excellence for Oral Contraceptives under Patheon's proprietary Quick to Clinic program.